{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:52Z","timestamp":1792788292060,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0520305"],"award-info":[{"award-number":["2024ZD0520305"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0520305"],"award-info":[{"award-number":["2024ZD0520305"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0520305"],"award-info":[{"award-number":["2024ZD0520305"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0520305"],"award-info":[{"award-number":["2024ZD0520305"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0520305"],"award-info":[{"award-number":["2024ZD0520305"]}]},{"name":"National Natural Science Foundation of China","award":["82272909"],"award-info":[{"award-number":["82272909"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["82272909"],"award-info":[{"award-number":["82272909"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["82272909"],"award-info":[{"award-number":["82272909"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["82272909"],"award-info":[{"award-number":["82272909"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["82272909"],"award-info":[{"award-number":["82272909"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hebei Provincial Major Science and Technology Support Program for Biomedical Innovation","award":["242W7711Z"],"award-info":[{"award-number":["242W7711Z"]}]},{"name":"Hebei Provincial Major Science and Technology Support Program for Biomedical Innovation","award":["242W7711Z"],"award-info":[{"award-number":["242W7711Z"]}]},{"name":"Hebei Provincial Major Science and Technology Support Program for Biomedical Innovation","award":["242W7711Z"],"award-info":[{"award-number":["242W7711Z"]}]},{"name":"Hebei Provincial Major Science and Technology Support Program for Biomedical Innovation","award":["242W7711Z"],"award-info":[{"award-number":["242W7711Z"]}]},{"name":"Hebei Provincial Major Science and Technology Support Program for Biomedical Innovation","award":["242W7711Z"],"award-info":[{"award-number":["242W7711Z"]}]},{"name":"Industry-University-Research Innovation Fund for Chinese Universities","award":["2025XH001"],"award-info":[{"award-number":["2025XH001"]}]},{"name":"Industry-University-Research Innovation Fund for Chinese Universities","award":["2025XH001"],"award-info":[{"award-number":["2025XH001"]}]},{"name":"Industry-University-Research Innovation Fund for Chinese Universities","award":["2025XH001"],"award-info":[{"award-number":["2025XH001"]}]},{"name":"Industry-University-Research Innovation Fund for Chinese Universities","award":["2025XH001"],"award-info":[{"award-number":["2025XH001"]}]},{"name":"Industry-University-Research Innovation Fund for Chinese Universities","award":["2025XH001"],"award-info":[{"award-number":["2025XH001"]}]},{"name":"Hebei Medical Science Research Project","award":["20200068"],"award-info":[{"award-number":["20200068"]}]},{"name":"Research Fund of The Second Hospital of Hebei Medical University","award":["2HY202555"],"award-info":[{"award-number":["2HY202555"]}],"id":[{"id":"https:\/\/ror.org\/015ycqv20","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Central Government Guidance Fund for Local Science and Technology Development","award":["264Z7732G"],"award-info":[{"award-number":["264Z7732G"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acquired resistance to oxaliplatin limits the efficacy of first-line chemotherapy in colorectal cancer (CRC), yet the stress-responsive signaling mechanisms that enable tumor cells to adapt to platinum-induced DNA damage remain incompletely understood. CD55, a glycosylphosphatidylinositol-anchored complement regulator, has recently been implicated in non-canonical cellular stress signaling beyond its classical immune-modulatory role. Here, we investigated whether stress-induced CD55 signaling contributes to oxaliplatin resistance by modulating DNA damage response and repair capacity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Oxaliplatin-resistant CRC cell lines were established through stepwise dose escalation. RNA sequencing with cross-validation against public datasets was used to identify candidate resistance genes. CD55 function was assessed using knockdown and overexpression approaches across seven CRC cell lines. Clinical correlations were evaluated using TCGA and GEO datasets. Homologous recombination (HR) capacity was measured using the DR-GFP reporter system, and DNA damage dynamics were assessed by \u03b3-H2AX foci formation and comet assays. Drug interactions between oxaliplatin and PARP inhibitors were analyzed using the Chou\u2013Talalay method. In vivo efficacy was evaluated in xenograft models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CD55 was consistently upregulated in oxaliplatin-resistant CRC cells across three independent datasets and was induced by oxaliplatin treatment in a dose- and time-dependent manner, with stress-associated nuclear translocation observed following DNA damage. CD55 depletion sensitized all seven CRC cell lines to oxaliplatin (approximately 1.2- to 5.4-fold), with at least one siRNA reaching statistical significance in every line, irrespective of microsatellite instability or p53 status. In patient cohorts, elevated CD55 expression predicted poor response to FOLFOX therapy and independently correlated with reduced disease-free survival (hazard ratio\u2009=\u20093.47). Mechanistically, CD55 expression inversely correlated with genomic instability markers, and CD55 depletion significantly reduced HR efficiency in both parental and oxaliplatin-resistant CRC cells (~\u200940\u201346% reduction), impaired BRCA1 induction, and prolonged \u03b3-H2AX accumulation. In oxaliplatin-resistant cells, CD55 depletion converted the antagonistic oxaliplatin\u2013olaparib interaction toward synergy in a dose-ratio\u2013dependent manner (synergistic at 3:1 and 1:3, additive at 1:1; mean CI 0.58\u20130.95), reaching significance at the 3:1 ratio (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.025). In xenograft models, CD55 depletion combined with dual-agent treatment reduced tumor burden by 62.8% in HCT116-OXR and consistently across all treatment arms in HT29-OXR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CD55 acts as a stress-responsive signaling regulator that partially supports homologous recombination capacity under genotoxic stress and promotes oxaliplatin resistance in CRC. These findings identify CD55 as both a predictive biomarker and a therapeutic vulnerability, and demonstrate that CD55 depletion can induce a partial HR impairment \u2014 operationally described as a \u201cBRCAness-like\u201d state \u2014 that is sufficient to sensitize HR-proficient tumors to PARP inhibition, thereby expanding the potential utility of PARP inhibitor\u2013based combination strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-026-03047-z","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:33:33Z","timestamp":1783665213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stress-induced CD55 supports homologous recombination capacity and drives oxaliplatin resistance in colorectal cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Tianyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianmei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"3047_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","volume":"404","author":"C Eng","year":"2024","unstructured":"Eng C, Yoshino T, Ru\u00edz-Garc\u00eda E, Mostafa N, Cann CG, O\u2019Brian B, Benny A, Perez RO, Cremolini C. Colorectal cancer. Lancet (London England). 2024;404:294\u2013310. https:\/\/doi.org\/10.1016\/S0140-6736(24)00360-X.","journal-title":"Lancet (London England)"},{"key":"3047_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N, Bray F. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72:338\u201344. https:\/\/doi.org\/10.1136\/gutjnl-2022-327736.","journal-title":"Gut"},{"key":"3047_CR3","doi-asserted-by":"publisher","first-page":"101152","DOI":"10.1016\/j.drup.2024.101152","volume":"77","author":"S Luo","year":"2024","unstructured":"Luo S, Yue M, Wang D, Lu Y, Wu Q, Jiang J. Breaking the barrier: Epigenetic strategies to combat platinum resistance in colorectal cancer. Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother. 2024;77:101152. https:\/\/doi.org\/10.1016\/j.drup.2024.101152.","journal-title":"Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother"},{"key":"3047_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","volume":"21","author":"S Rottenberg","year":"2021","unstructured":"Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21:37\u201350. https:\/\/doi.org\/10.1038\/s41568-020-00308-y.","journal-title":"Nat Rev Cancer"},{"key":"3047_CR5","doi-asserted-by":"publisher","first-page":"9537","DOI":"10.1093\/nar\/gky764","volume":"46","author":"J Slyskova","year":"2018","unstructured":"Slyskova J, Sabatella M, Ribeiro-Silva C, Stok C, Theil AF, Vermeulen W, Lans H. Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage. Nucleic Acids Res. 2018;46:9537\u201349. https:\/\/doi.org\/10.1093\/nar\/gky764.","journal-title":"Nucleic Acids Res"},{"key":"3047_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9\u201323.","journal-title":"Cancer Treat Rev"},{"key":"3047_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573\u201384.","journal-title":"Nat Rev Cancer"},{"key":"3047_CR8","doi-asserted-by":"publisher","unstructured":"Wright WD, Shah SS, Heyer W. Homologous recombination and the repair of DNA double-strand breaks. J Biol Chem 2018, 293, 10524\u201335, https:\/\/doi.org\/10.1074\/jbc.TM118.000372","DOI":"10.1074\/jbc.TM118.000372"},{"key":"3047_CR9","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","volume":"66","author":"N McCabe","year":"2006","unstructured":"McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O\u2019Connor MJ, Tutt AN, Zdzienicka MZ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0140.","journal-title":"Cancer Res"},{"key":"3047_CR10","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137.","journal-title":"Nature"},{"key":"3047_CR11","doi-asserted-by":"publisher","first-page":"114036","DOI":"10.1016\/j.ejca.2024.114036","volume":"205","author":"A Takashima","year":"2024","unstructured":"Takashima A, Garc\u00eda-Alfonso P, Manneh R, Be\u015fen AA, Hong YS, Cuyle PJ, Yanez P, Burge M, Yoshino T, Kim TW, et al. Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. Eur J Cancer. 2024;205:114036. https:\/\/doi.org\/10.1016\/j.ejca.2024.114036.","journal-title":"Eur J Cancer"},{"key":"3047_CR12","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/1078-0432.CCR-19-2409","volume":"26","author":"S Arena","year":"2020","unstructured":"Arena S, Corti G, Durinikova E, Montone M, Reilly NM, Russo M, Lorenzato A, Arcella P, Lazzari L, Rospo G, et al. A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin. Clin Cancer Res. 2020;26:1372\u201384. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2409.","journal-title":"Clin Cancer Res"},{"key":"3047_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jmg.2006.048173","volume":"44","author":"L Kadouri","year":"2007","unstructured":"Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, Abeliovich D, Peretz T. Cancer risks in carriers of the BRCA1\/2 Ashkenazi founder mutations. J Med Genet. 2007;44:467\u201371. https:\/\/doi.org\/10.1136\/jmg.2006.048173.","journal-title":"J Med Genet"},{"key":"3047_CR14","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1200\/JCO.2016.71.0012","volume":"35","author":"MB Yurgelun","year":"2017","unstructured":"Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, Mcnamara PG, Mayer RJ, et al. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. 2017;35:1086\u201395. https:\/\/doi.org\/10.1200\/JCO.2016.71.0012.","journal-title":"J Clin Oncol"},{"key":"3047_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.annonc.2020.05.027","volume":"31","author":"G Mauri","year":"2020","unstructured":"Mauri G, Arena S, Siena S, Bardelli A, Sartore-Bianchi A. The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Ann Oncol. 2020;31:1135\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.027.","journal-title":"Ann Oncol"},{"key":"3047_CR16","doi-asserted-by":"publisher","unstructured":"Abbotts R, Dellomo AJ, Rassool FV. Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use. Volume 14. Cancers; 2022. https:\/\/doi.org\/10.3390\/cancers14112640.","DOI":"10.3390\/cancers14112640"},{"key":"3047_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A. Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Cancer. 2004;4:814\u20139. https:\/\/doi.org\/10.1038\/nrc1457.","journal-title":"Nat Rev Cancer"},{"key":"3047_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16:110\u201320. https:\/\/doi.org\/10.1038\/nrc.2015.21.","journal-title":"Nat Rev Cancer"},{"key":"3047_CR19","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3389\/fimmu.2019.01074","volume":"10","author":"A Geller","year":"2019","unstructured":"Geller A, Yan J. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy. Front Immunol. 2019;10:1074. https:\/\/doi.org\/10.3389\/fimmu.2019.01074.","journal-title":"Front Immunol"},{"key":"3047_CR20","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/BF02841003","volume":"6","author":"Y Liu","year":"2005","unstructured":"Liu Y, Chen L, Peng S, Chen Z, Hoang-Vu C. Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci B. 2005;6:913\u20138.","journal-title":"J Zhejiang Univ Sci B"},{"key":"3047_CR21","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.4251\/wjgo.v16.i5.2168","volume":"16","author":"X Zhu","year":"2024","unstructured":"Zhu X, Zhang L, Qi S. Association of complement components with risk of colorectal cancer: A systematic review and meta-analysis. World J Gastrointest Oncol. 2024;16:2168\u201380. https:\/\/doi.org\/10.4251\/wjgo.v16.i5.2168.","journal-title":"World J Gastrointest Oncol"},{"key":"3047_CR22","doi-asserted-by":"crossref","unstructured":"Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunology, Immunotherapy: CII 2003, 52, 638\u2013642.","DOI":"10.1007\/s00262-003-0402-y"},{"key":"3047_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.neo.2018.12.005","volume":"21","author":"GB Park","year":"2019","unstructured":"Park GB, Kim D. MicroRNA-503-5p Inhibits the CD97-Mediated JAK2\/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells. Neoplasia. 2019;21:206\u201315. https:\/\/doi.org\/10.1016\/j.neo.2018.12.005.","journal-title":"Neoplasia"},{"key":"3047_CR24","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1084\/jem.20170438","volume":"214","author":"C Saygin","year":"2017","unstructured":"Saygin C, Wiechert A, Rao VS, Alluri R, Connor E, Thiagarajan PS, Hale JS, Li Y, Chumakova A, Jarrar A, et al. CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. J Exp Med. 2017;214:2715\u201332. https:\/\/doi.org\/10.1084\/jem.20170438.","journal-title":"J Exp Med"},{"key":"3047_CR25","doi-asserted-by":"publisher","first-page":"215935","DOI":"10.1016\/j.canlet.2022.215935","volume":"551","author":"R Bharti","year":"2022","unstructured":"Bharti R, Dey G, Lin F, Lathia J, Reizes O. CD55 in cancer: Complementing functions in a non-canonical manner. Cancer Lett. 2022;551:215935. https:\/\/doi.org\/10.1016\/j.canlet.2022.215935.","journal-title":"Cancer Lett"},{"key":"3047_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12943-024-02028-5","volume":"23","author":"R Bharti","year":"2024","unstructured":"Bharti R, Dey G, Khan D, Myers A, Huffman OG, Saygin C, Braley C, Richards E, Sangwan N, Willard B, et al. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer. Mol Cancer. 2024;23:121. https:\/\/doi.org\/10.1186\/s12943-024-02028-5.","journal-title":"Mol Cancer"},{"key":"3047_CR27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3748\/wjg.v29.i9.1395","volume":"29","author":"BS Al","year":"2023","unstructured":"Al BS, El-Sabban M, Doughan S, Abou-Kheir W. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World J Gastroenterol. 2023;29:1395\u2013426. https:\/\/doi.org\/10.3748\/wjg.v29.i9.1395.","journal-title":"World J Gastroenterol"},{"key":"3047_CR28","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1038\/oncsis.2013.35","volume":"2","author":"D Ahmed","year":"2013","unstructured":"Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Ekn\u00e6s M, Hektoen M, Lind GE, Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013;2:e71. https:\/\/doi.org\/10.1038\/oncsis.2013.35.","journal-title":"Oncogenesis"},{"key":"3047_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1155\/2006\/814816","volume":"28","author":"JH Mikesch","year":"2006","unstructured":"Mikesch JH, Schier K, Roetger A, Simon R, Buerger H, Brandt B. The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol. 2006;28:223\u201332. https:\/\/doi.org\/10.1155\/2006\/814816.","journal-title":"Cell Oncol"},{"key":"3047_CR30","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","volume":"11","author":"L Nguyen","year":"2020","unstructured":"Nguyen L, W MMJ, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11:5584. https:\/\/doi.org\/10.1038\/s41467-020-19406-4.","journal-title":"Nat Commun"},{"key":"3047_CR31","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1038\/oncsis.2016.20","volume":"5","author":"F Cimmino","year":"2016","unstructured":"Cimmino F, Avitabile M, Pezone L, Scalia G, Montanaro D, Andreozzi M, Terracciano L, Iolascon A, Capasso M. CD55 is a HIF-2\u03b1 marker with anti-adhesive and pro-invading properties in neuroblastoma. Oncogenesis. 2016;5:e212. https:\/\/doi.org\/10.1038\/oncsis.2016.20.","journal-title":"Oncogenesis"},{"key":"3047_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-025-02148-4","volume":"10","author":"Y Li","year":"2025","unstructured":"Li Y, Liu F, Cai Q, Deng L, Ouyang Q, Zhang XH, Zheng J. Invasion and metastasis in cancer: molecular insights and therapeutic targets. Signal Transduct Target Ther. 2025;10:57. https:\/\/doi.org\/10.1038\/s41392-025-02148-4.","journal-title":"Signal Transduct Target Ther"},{"key":"3047_CR33","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.3892\/or.2019.7337","volume":"42","author":"SH Dho","year":"2019","unstructured":"Dho SH, Cho EH, Lee JY, Lee SY, Jung SH, Kim LK, Lim JC. A novel therapeutic anti\u2013CD55 monoclonal antibody inhibits the proliferation and metastasis of colorectal cancer cells. Oncol Rep. 2019;42:2686\u201393. https:\/\/doi.org\/10.3892\/or.2019.7337.","journal-title":"Oncol Rep"},{"key":"3047_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5:387\u201393. https:\/\/doi.org\/10.1016\/j.molonc.2011.07.001.","journal-title":"Mol Oncol"},{"key":"3047_CR35","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. Immune Landsc Cancer Immun. 2018;48:812\u2013e83014. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023.","journal-title":"Immune Landsc Cancer Immun"},{"key":"3047_CR36","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1053\/j.gastro.2009.11.005","volume":"138","author":"JJ Smith","year":"2010","unstructured":"Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138:958\u201368. https:\/\/doi.org\/10.1053\/j.gastro.2009.11.005.","journal-title":"Gastroenterology"},{"key":"3047_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2017.02.003","volume":"76","author":"RM Del","year":"2017","unstructured":"Del RM, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, et al. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. Eur J Cancer. 2017;76:68\u201375. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.003.","journal-title":"Eur J Cancer"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-03047-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03047-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03047-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:01:41Z","timestamp":1791313301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-03047-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3047"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-03047-z","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures were approved by and complied with the guidelines of the Ethics Committee of the Second Hospital of Hebei Medical University. This study utilized publicly available, de-identified patient datasets from TCGA and GEO databases; therefore, no additional ethical approval or informed consent was required for the bioinformatics analyses of human data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"532"}}